AbbVie’s New Schizophrenia Drug Suffers Major Setback in Clinical Trials

AbbVie’s New Schizophrenia Drug Suffers Major Setback in Clinical Trials
1 month ago

AbbVie, the biopharmaceutical giant known for its innovative drug portfolio, has experienced a significant downturn following disappointing results from two large-scale clinical trials of its investigational drug for schizophrenia. This development has sent ripples through the pharmaceutical sector, resulting in a substantial drop in the company’s stock price.

Continue reading
AbbVie Raises Profit Outlook as Rinvoq and Skyrizi Outperform Expectations

AbbVie Raises Profit Outlook as Rinvoq and Skyrizi Outperform Expectations
2 months ago

In a significant update from the biopharmaceutical giant AbbVie, the company has revised its profit expectations upward following strong performance from its inflammatory drugs, Rinvoq and Skyrizi. This development, reported on October 30, 2024, signals a promising trend in AbbVie's growth strategy and showcases the resilience of its product pipeline amidst a competitive market landscape.

Continue reading